If you’re seeing Mounjaro mentioned everywhere and wondering whether it’s actually approved for weight loss in the UK, the confusion is normal because “approved”, “recommended”, and “available on the NHS” are three different things.

Table of Contents

Quick answer

Yes. Mounjaro (tirzepatide) is authorised in the UK for weight management (including weight loss) by the MHRA. That authorisation sets the legal “licence” for who it can be prescribed to and under what conditions.

But whether you can get it (and where) depends on:

NICE guidance (who it’s recommended for in NHS care), and
NHS rollout rules and services (how access is phased, and what support must come with it).

You can also read the main product hub here: Mounjaro weight loss injection pen.

What “approved” means in the UK (MHRA authorisation)

In the UK, the MHRA is the regulator that decides whether a medicine is authorised (licensed) for a specific use. For Mounjaro, the MHRA expanded authorisation so it can be used for weight management and weight loss in adults who meet certain criteria alongside diet and physical activity changes.

Key point:
If a medicine is MHRA-authorised for weight management, a prescriber can prescribe it within that licence but that doesn’t automatically mean the NHS will provide it to everyone who qualifies.

MHRA vs NICE vs NHS: why people get confused

Here’s the simplest way to separate the roles:

Topic	Who decides?	What it affects for you
Is it licensed/authorised for weight loss?	MHRA	Whether it can legally be prescribed for that purpose
Is it recommended as cost-effective in NHS care (and for whom)?	NICE	Who it’s recommended for, thresholds, stop rules, required support
How and when NHS patients can access it?	NHS England (and local services/ICBs)	Rollout phases, service routes, eligibility prioritisation, wraparound care

So: MHRA = licence, NICE = recommendations, NHS = delivery + capacity.

NICE guidance (TA1026): who tirzepatide is recommended for

NICE issued Technology Appraisal guidance TA1026 for tirzepatide for managing overweight and obesity.

In NHS practice, NICE recommendations are often more specific than the broad “licensed” population because they also consider:

cost effectiveness,
service capacity,
required behavioural/lifestyle support.

Typical NICE threshold (high-level)

NICE’s TA1026 framework uses thresholds such as:

BMI ≥ 35 kg/m², and
at least 1 weight-related comorbidity,
with lower BMI thresholds (often reduced by 2.5 kg/m²) for certain ethnic backgrounds due to higher cardiometabolic risk at lower BMI.

“Support with diet and exercise” is not optional

NICE’s approach is built around the idea that medication should be combined with structured support, not used as a standalone solution.

NHS access: can you get Mounjaro for weight loss on the NHS?

NHS access is the part that changes most over time because it depends on rollout planning, services, and funding.

1) Specialist weight management services (starting point)

NHS England states that from 23 March 2025, tirzepatide (Mounjaro) for weight management may be prescribed only if prescribed by a specialist weight management service, where clinicians decide it’s appropriate, and where wider support is available.

2) Phased rollout and prioritisation

NHS England commissioning materials describe the need for phased access because demand is high and resources (clinics, staff, monitoring, behavioural support) are limited.

3) Primary care involvement + wraparound behavioural support

NHS England has also published guidance on tirzepatide in primary care and emphasises that the MHRA licence and NICE guidance require behavioural support alongside medication meaning access isn’t just “a prescription”; it must come with structured support.

Practical takeaway:
Even if you meet clinical thresholds, you may still face staged access depending on local availability and how your area is implementing services.

What about private prescriptions in the UK?

Because the MHRA licence exists, private prescriptions can be offered but legitimacy depends on how the prescription is issued, not on social media claims.

A credible private pathway usually includes:

a structured clinical assessment (BMI, comorbidities, contraindications, current meds),
patient safety checks and monitoring plan,
clear education on injection use, side effects, and escalation advice,
appropriate follow-up,
and supply from regulated pharmacies.

Also note: official patient information for Mounjaro in the UK includes weight loss/maintenance use and practical instructions and safety details.

Eligibility checklist (simple decision filter)

This is not a diagnosis it’s a fast filter to help you understand whether you’re likely within the typical UK weight-management criteria.

You’re more likely to be considered if:

Your BMI is high enough (often ≥35 in NHS NICE-based pathways), and
You have at least one weight-related health problem (e.g., hypertension, dyslipidaemia, prediabetes, etc.),
You can commit to reduced-calorie diet + activity changes, and
You will receive behavioural/lifestyle support alongside the medication.

Next-step action rules

If you’re researching basics: start with What is Mounjaro for weight loss?
If you’re deciding between injections: read Mounjaro vs Wegovy
If you want mechanism clarity: read How Mounjaro works for weight loss
If you want the full product overview + next steps: go to Mounjaro weight loss injection pen

FAQs

Is Mounjaro licensed in the UK for weight loss?

Yes. The MHRA authorised Mounjaro (tirzepatide) for weight management and weight loss for eligible adults, alongside diet and physical activity.

If it’s approved, why can’t everyone get it on the NHS?

Because NHS access depends on NICE recommendations, commissioning decisions, and service capacity, and rollout is phased with prioritisation.

Can my GP prescribe it for weight loss?

In NHS pathways, NHS England information has indicated access initially through specialist weight management services, with evolving guidance including primary care frameworks tied to wraparound behavioural support.

Do I need lifestyle support to use it?

Yes both NHS guidance and documentation highlight that medication should be combined with behavioural/lifestyle support.